- Home
- BME vs KURA Comparison
BME vs KURA Comparison
Compare BME & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- KURA
- Stock Information
- Founded
- BME 2005
- KURA 2014
- Country
- BME United States
- KURA United States
- Employees
- BME N/A
- KURA N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BME Finance
- KURA Health Care
- Exchange
- BME Nasdaq
- KURA Nasdaq
- Market Cap
- BME 462.3M
- KURA 492.9M
- IPO Year
- BME N/A
- KURA N/A
- Fundamental
- Price
- BME $36.54
- KURA $6.00
- Analyst Decision
- BME
- KURA Strong Buy
- Analyst Count
- BME 0
- KURA 11
- Target Price
- BME N/A
- KURA $23.89
- AVG Volume (30 Days)
- BME 34.0K
- KURA 1.5M
- Earning Date
- BME 01-01-0001
- KURA 05-01-2025
- Dividend Yield
- BME 6.26%
- KURA N/A
- EPS Growth
- BME N/A
- KURA N/A
- EPS
- BME 1.44
- KURA N/A
- Revenue
- BME N/A
- KURA $67,991,000.00
- Revenue This Year
- BME N/A
- KURA $44.32
- Revenue Next Year
- BME N/A
- KURA $173.73
- P/E Ratio
- BME $28.37
- KURA N/A
- Revenue Growth
- BME N/A
- KURA N/A
- 52 Week Low
- BME $35.53
- KURA $5.41
- 52 Week High
- BME $43.20
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- BME 45.11
- KURA 43.30
- Support Level
- BME $36.09
- KURA $6.20
- Resistance Level
- BME $37.65
- KURA $6.76
- Average True Range (ATR)
- BME 0.52
- KURA 0.35
- MACD
- BME 0.11
- KURA -0.00
- Stochastic Oscillator
- BME 53.16
- KURA 40.62
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.